ClinicalTrials.gov
public full text
Public Domain
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
* 1\. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC). * 2\. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment. * 3\. There is no trial of axitinib for non-clear cell RCC. * 4\. Axitinib is expected to show more potent efficacy over sorafenib or sunitinib in renal cell carcinoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib Dose Escalation in Renal Cell Carcinoma#1127978
- NeoVax Plus Ipilimumab in Renal Cell Carcinoma#895829
- Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma#803839
- Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment#890566
- Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma#970011
Record · ID 865820
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive